Custom Search

Brand Name(s): RP 62955
CAS nš: 133737-32-3
(pa GA klone)

What is Pagaclone?

Pagaclone or pagoclone was originally developed as an antianxiety drug, and is currently undergoing clinical development.

This medication is a novel member of the cyclopyrrolone class of compounds and acts as a gamma amino butyric acid (GABA) selective receptor modulator. Its is thought that pagoclone increases the action of GABA in the brain, which reduces excess neuronal activity and thereby has the potential to alleviate symptoms of general panic attacks and anxiety disorders.

Additionally, further clinical trials are being carried out on pagaclone (pagoclone) as it may also reduce the severity of other disorders, including persistent developmental stuttering (PDS).
 

See more Product Info

Latest News

Women More Prone to Anxiety Disorders than Men, Says a New Report from Harvard Medical School

Boston -- Many types of anxiety disorders and phobias are more common in women than in men, says...

[more]

A Pill for Stuttering

New Drug May Change Treatment of Common Speech Disorder

[more]

Indevus Announces Promising Phase II Data for Pagoclone In Stuttering

Indevus Pharmaceuticals, Inc. today announced top line results from the Company's Phase II clinical...

[more]

Study Ties Stuttering to Anatomical Differences in the Brain

Stuttering has been long thought to be caused by emotional factors, but researchers who studied...

[more]

Pagoclone Significantly Reduces Frequency Of Panic Attacks

Interneuron Pharmaceuticals, Inc. today announced that a Phase II study among patients suffering...

[more]

Use of this site is subject to the following terms of use